4 Penny Stocks Reddit Traders Are Buying Right Now entrepreneur.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from entrepreneur.com Daily Mail and Mail on Sunday newspapers.
Share:
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) Bionano Genomics, Inc. (NASDAQ:BNGO) announced today that company management will present virtually at the Oppenheimer MedTech, Tools & Diagnostics Summit being held on May 26, 2021.
The presentation will be available to view on the Events page in the Investors section of Bionano s website and at Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com) on May 26, 2021 at 8am ET. The webcast of the event will be archived on Bionano s website for 30 days following the event.
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation
Avinger To Present at the Oppenheimer MedTech, Tools & Diagnostics Summit May 26
ACCESSWIRE
17 May 2021, 22:05 GMT+10
REDWOOD CITY, CA / ACCESSWIRE / May 17, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will host investor meetings on May 26, 2021 as part of the Oppenheimer MedTech, Tools & Diagnostics Summit.
Institutional investors that wish to schedule a meeting with management can contact their Oppenheimer sales representative or Matt Kreps, Investor Relations for Avinger, at mkreps@darrowir.com.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 mil